PROSHARES TRUST's ProShares Ultra Nasdaq Biotechnology (BIB) has disclosed 217 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-05-31. The current portfolio value is calculated to be $61.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 0%.
ProShares Ultra Nasdaq Biotechnology (BIB)'s
Total Assets is $90.63 Mil , Total Liabilities is $2.36 Mil , Net Assets is $88.27 Mil.
In ProShares Ultra Nasdaq Biotechnology (BIB)'s current portfolio as of 2024-05-31, the top 5 holdings are
Amgen Inc (AMGN), Vertex Pharmaceuticals Inc (VRTX), Regeneron Pharmaceuticals Inc (REGN), Gilead Sciences Inc (GILD) and Moderna Inc (MRNA),
not including call and put options.
ProShares Ultra Nasdaq Biotechnology (BIB) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for ProShares Ultra Nasdaq Biotechnology (BIB), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for ProShares Ultra Nasdaq Biotechnology (BIB), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for ProShares Ultra Nasdaq Biotechnology.